USP7 and synovial sarcoma: Accordingly, synovial sarcoma cells (as represented by two cell lines and one organoid model) displayed markedly higher sensitivity to incremental doses of the USP7 inhibitor FT827 than Ewing sarcoma cells (Fig S8E).